Browse the detailed record of transactions filed by ROBINS HARLAN S, Chief Scientific Officer. Officer active across 1 companies, notably Adaptive Biotechnologies Corp. In total, 31 reports have been published. Total volume traded: €2.8m. The latest transaction was disclosed on 8 April 2026 — Cession. Regulator: SEC (Form 4). All data is accessible without signup.
25 of 31 declarations
Dr. Harlan S. Robins is the Chief Scientific Officer and co-founder of Adaptive Biotechnologies, a U.S.-listed commercial-stage biotechnology company focused on translating the adaptive immune system into clinical and research products. In this role, he serves as a key scientific leader for the company, helping shape its immune-profiling platform and the broader research strategy behind its diagnostics and therapeutic applications. Public company materials identify him as one of Adaptive’s core executive leaders and a long-standing member of its governance structure. ([adaptivebiotech.com](https://www.adaptivebiotech.com/adaptive-leadership/harlan-robins/?utm_source=openai)) Before co-founding Adaptive, Robins spent several years at the Fred Hutchinson Cancer Research Center, where he held multiple positions in the Computational Biology Program, including Assistant Faculty Member, Associate, Full Member, and ultimately Head of the program. That trajectory reflects a career built in academic research and computational biology, with work spanning bioinformatics, genomics, and quantitative methods applied to life sciences problems. Biographical sources note that he focused on developing algorithms for microRNA targets and bacterial genome analysis, laying groundwork for later biomedical applications. ([adaptivebiotech.com](https://www.adaptivebiotech.com/adaptive-leadership/harlan-robins/?utm_source=openai)) Robins’ educational background is highly interdisciplinary. He earned a BS in Physics from Harvard University, followed by a master’s degree and PhD in Physics from the University of California, Berkeley. He also completed postdoctoral appointments at the Weizmann Institute of Science in Israel and at the Institute for Advanced Study in Princeton. This mix of physics, mathematics, and computational science has been central to his ability to apply rigorous analytical methods to immunology and molecular biology. ([adaptivebiotech.com](https://www.adaptivebiotech.com/adaptive-leadership/harlan-robins/?utm_source=openai)) His notable achievements are tied to the scientific foundation of Adaptive Biotechnologies. He is associated with co-building the company’s immune-system analytics approach, which aims to convert immune-repertoire information into clinical insights and research tools. Recent company disclosures continue to list him in senior leadership and governance roles, underscoring his lasting influence on the company’s scientific direction and corporate oversight. ([adaptivebiotech.com](https://www.adaptivebiotech.com/adaptive-leadership/harlan-robins/?utm_source=openai))